

*Original Research Article*

**Detection of *bla<sub>NDM</sub>* -Metallo- $\beta$ -Lactamase Genes in *Klebsiella pneumoniae* Strains Isolated From Burn Patients in Baghdad Hospitals**

Abbas Atyia Hammoudi<sup>1\*</sup> Azhar Noori Hussein<sup>2</sup> Mohammed Shamkhi Jebur<sup>3</sup>

<sup>1</sup>Institute of Medical Technology/Baghdad, Middle Technical University

<sup>2</sup>College of Pharmacy, Al-Qadisiha University

<sup>3</sup>College of Health and Medical Technology

\*E. mail: hammoudi.abbas@yahoo.com

Accepted 12 February, 2017

**Abstract**

From the period from March to August 2016, 210 swabs were collected from the burn patients hospitalized in different hospitals in Baghdad City: Al-Karama Teaching Hospital, Special Burn Hospital, Central Teaching Laboratories, Child protection Teaching Hospital, Imam Ali Hospital. Out of 210 clinical isolates, 42 (37.5 %) had been shown a single isolated of pathogenic bacteria *K. pneumoniae* and the others were belonged to other bacteria and mixed growth isolates. Identification of all isolates were carried out depending on macroscopic, microscopic characterizations, conventional biochemical tests and Api 20E system. Metallo- $\beta$  lactamase (MBL) enzymes were screen by two phenotypic methods (Meropenem-EDTA double disks method and Modified Hodg test). Susceptibility testing were used with The following antibiotic disks: Imipenem, Meropenem, Ceftazidime, Cefotaxime, Piperacillin, Gentamicin, Amikacin and Ciprofloxacin. The percentage of resistance isolates were as followed: Imipenem (21.42%), Meropenem (19.04%), Ceftazidime (69.04%), Cefotaxime (85.71%), Piperacillin (85.71%), Gentamicin (26.19%), Amikacin (19.04 %) and Ciprofloxacin (59.52%). The percentage of the prevalence of *bla<sub>NDM-1</sub>* and *bla<sub>NDM-2</sub>* genes in *K. pneumoniae* isolates from burn patients in Baghdad hospitals were as followed: 20 (100 %) for *bla<sub>NDM-1</sub>* genes and 6 (30 %) for *bla<sub>NDM-2</sub>* genes.

**Key Words:** Burn Patients, *bla<sub>NDM</sub>* -Metallo- $\beta$ -Lactamase Genes, *Klebsiella pneumoniae*.

**الخلاصة**

جمعت 210 مسحات قطنية للفترة من اذار ولغاية اب 2016 من مرضى الحروق الراقدين في مستشفيات مختلفة في مدينة بغداد: مستشفى الكرامة التعليمي, مستشفى الحروق التخصصي, المختبرات التعليمية المركزية, مستشفى حماية الاطفال التعليمي ومستشفى الامام علي , تم تشخيص 42 عزلة (37,5 %) للكليسيلا الرئوية كعزلات مفردة من 210 عزلة, اما بقية العزلات فكانت لبكتيريا اخرى اعتمادا على الصفات المظهرية والمجهريه والفحوصات الكيموحياتية , وتم تأكيد التشخيص باستعمال نظام Api 20 E تم استخدام طريقتين التوصيف المظهري للكشف عن انزيمات البيبتالاكتيميز المعدنية CMDT, MHT. اظهرت عزلات الكليسيلا الرئوية نسبة مقاومة للمضادات الحيوية الاتية وعلى التوالي: اميبينيم, ميروبيينيم, سفتادزيم, سيفوتاكسيم, بيراسلين, جنتامايسين, اميكاسين و سيروفلوكساسين .: (59.52%) (19.04 %), (26.19%), (85.71%), (85.71%), (69.04%), (19.04%), (21.42%) وكانت نسبة انتشار جينات انزيمات البيبتالاكتيميز المعدنية -1 بلغت 20 (100%) ونسبة انتشار جينات انزيمات البيبتالاكتيميز المعدنية-2 بلغت 6 (30 %).

**الكلمات المفتاحية :** مرضى الحروق , جينات انزيمات البيبتالاكتيميز المعدنية , الكليسيلا الرئوية.

## **Introduction**

**K**lebsiella pneumoniae was an opportunistic gram-negative pathogenic bacterium associated with a range of nosocomial infections (e.g. septicemia, pneumonia, bacteremia, meningitis, urinary tract, burn and wound infections) [1]. Furthermore it was the most medically important species of the genus *Klebsiella*. In recent years, *Klebsiella* have become important pathogens in nosocomial infections [2]. It was also a potential community – acquired pathogen [3]. Antibiotic therapies are widely used for treating infectious diseases. Nowadays, antibiotic-resistant bacteria are a great concern of worldwide public health [4]. The problem of antimicrobial resistance is highlighted by a recent increase of carbapenem-resistant *K. pneumoniae*, which has largely been driven by the emergence and spread of mobile genetic elements carrying carbapenemase resistance genes including the metallo-beta-lactamase [5, 6]. Meropenem and imipenem are carbapenems that remain active against organisms carrying most Ambler classes of  $\beta$ -lactamases which include many Gram-negative bacilli, including *Klebsiella* spp. One of the major mechanisms of carbapenem resistance in this pathogen is the production of carbapenem hydrolyzing  $\beta$ -lactamases. These specific groups of  $\beta$ -lactamases are categorized into class B metallo  $\beta$ -lactamases (MBLs) including Imipenemase (*IMP*) and Verona integrin encoded metallo-lactamase (*VIM*), New Delhi metallo-beta-lactamase (*NDMs*) and class D (Oxacillinases) including *OXA*-23-like, *OXA*-24/40-like and *OXA*-58 [7, 8]. The new MBL, New Delhi metallo- $\beta$ -lactamase (*NDM*-1), initially reported in *K. pneumoniae* and *E. coli* recovered from a Swedish patient who was previously hospitalized in India in 2008 [9]. The rapid emergence spread of *NDM* positive bacteria has a complex epidemiology involving a variety of harboring species (principally *Klebsiella pneumoniae* and *E. coli*), inter-strain, inter-species, and inter-genus transmission, which has been related to a

diverse moveable plasmid that can be transferred from one bacteria to another, from man to man and even from country to country in more than 40 countries worldwide [10,11]. The bacteria with *NDM*-1 gene are known as superbugs and public health must pay more attention to them [12]. Many phenotypic, genotypic, phylogenic and molecular methods used to detect the production of enzymes by bacteria that responsible about drug resistant which causes increased morbidity and mortality among patients with infections caused by these bacteria and increased healthcare costs due to the extended hospital stay [13]. In recent years, many Iraqi patients were travelled to India and to other countries for medical care purpose which may helped in acquiring *NDM* gene. In Iraq there were no information about the occurrence of *NDM*. *pneumoniae* producing clinical isolates. So the proposed aim of this study was to detect MBL genes <sup>bla</sup>*NDM*-1,2 among resistant isolates of *K. pneumoniae* obtained from burn patients in Baghdad Hospitals by polymerase chain reaction (PCR).

## **Material and Methods**

### **Isolation and Identification**

During the period from March to August 2016, 42 *K. pneumoniae* strains were isolated from 210 swabs of burn patients hospitalized in different hospitals in Baghdad City: Al-Karama Teaching Hospital, Special Burn Hospital, Central Teaching Laboratories, Child protection Teaching Hospital, Imam Ali Hospital. Specimens were collected by sterile swabs after the removal of dressing and cleaning the wound surface by 70% alcohol. The isolation and identification of *K. pneumoniae* from wound specimens were streaked on blood agar, MacConkey agar and Eosin methylene blue (EMB) agar (Biomark Lab. Pune. India) and incubated at 37°C for 24hrs. The isolates were identified as *K. pneumoniae* by manual biochemical tests that were used in accordance with the manufacturer's instructions; based on Gram staining,

catalase test, oxidase test, triple sugar iron (TSI) fermentation, Indole test, Voges-Proskauer (VP) test, Methyl red (MR) test, Simmons Citrate test, Urease test, motility test, and string test [14]. For final confirmation, biochemical tests embedded in the API-20E biochemical kit system (Bio-Merieux, France).

#### Antimicrobial Susceptibility Testing

The susceptibility pattern of isolates to different antibiotics were examined using

disk diffusion method (Kirby-Bauer) on Muller-Hinton agar plates (Biomark Lab., Pune, India) according to guidelines of CLSI [15]. The antimicrobial disks were included: Imipenem (10µg), Meropenem (10µg), Ceftazidime (30µg), Cefotaxime (30µg), Pipracillin (100µg), Gentamicin (10µg), Amikacin (30µg) and Ciprofloxacin (5µg) (MAST Co. UK). *Pseudomonas aeruginosa* ATCC27853 were used as a control strain [16].

**Table 1 :** Antibiotic disks used in this study

Antibiotic disks	Symbol	Disks potency (µg/ disk)	Company (origin)
Imipenem	IMP	10 µg	MAST Co. UK.
Meropenem	MEM	10 µg	
Ceftazidime	CAZ	30µg	
Cefotaxime	CTX	30µg	
Pipracillin	Pip	100µg	
Gentamicin	GM	10 µg	
Amikacin	AK	30µg	
Ciprofloxacin	CIP	5µg	

#### Screening for metallo $\beta$ -lactamases (MBL)

Meropenem-EDTA double disks method was performed using disks containing 1900 µg of EDTA plus 10 µg of Meropenem disks were placed on inoculated Muller Hinton agar plates. After 24hr. incubation, an increase of  $\geq 17$  mm in zone diameter in the presence of 1900 µg of EDTA compared to Meropenem disk alone were considered as MBL producing *K. pneumoniae* strains (positive results) [17].

#### Modified Hodge test (MHT)

Tested isolates were exposed to MHT test as recommended by [18]; Inoculating an overnight culture suspension of *E. coli* ATCC 25922 was streaked across the entire plate of Mueller-Hinton agar (MHA) plate. After drying 10 µg of Meropenem disk was placed at the center of the plate and up to 4 different isolates of tested organisms were streaked linearly from the periphery of the plate into the direction of Meropenem disk at the center

then the test plate was incubated at 37°C for 18 hours. The presence of a clover leaf-like shaped zone of inhibition around each tested strain is interpreted as Carbapenemases producing strain.

#### PCR amplification:

DNA was extracted from the isolates by using genomic extraction mini kit according to the manufacture instructions (Promega company, USA). To amplify the genes encoding carbapenemases, a PCR was run using the primers of NDM-1 and NDM-2 gene (Table-2) as described by [19]. Amplification was performed in a 20µl volume as recommended by Promega Master mix instruction. PCR amplifications were carried out on a thermal cycler (ESCO/USA). The cycling conditions for amplification were as follows: for *bla*NDM-1 and 2 genes, initial denaturation at 95°C for 5 min., 1 cycle, Denaturation at 95°C, 30 sec., Annealing at 55°C, 30 sec., Extension at 72°C for 30 sec., 30-35 cycles and Final Extension at 72°C. for 5 min., 1 cycle.

**Table 2 :** The sequences of primers used in PCR to detect *bla* NDM-1&2 [19].

Primer	Sequence	Amplicon size (bp)
<i>bla</i> NDM-1 Forward	'5-ATG GAA TTG CCC AAT ATT ATG C-3'	500bp
Reverse	'5-CGA AAG TCA GGC TGT GTT G-3'	
<i>bla</i> NDM-2 Forward	'5-CAC CTC ATG TTT GAA TTC GCC-3'	1000bp
Reverse	'5-CTC TGT CAC ATC GAA ATC GC-3'	

### Agarose Gel Electrophoresis

Amplified products were detected by agarose gel electrophoresis in 1% Tris-borate-EDTA (TBE) agarose (Promega USA), and staining with ethidium bromide, electric current was allowed at 70 volts for 2 hrs. DNA bands were observed using UV-Transilluminator and photographed with Gel documentation system. 100 bp DNA Ladder (Promega) was used to assess PCR product size [20].

### Results and Discussion

#### Bacterial strains, antibiotic susceptibility and MBL phenotypic test.

In this study a total of 210 sample swabs of clinical isolates of burn wound infections were cultured, examined and identified. Out of 210 clinical isolates, 42 (37.5 %) had been shown a single isolated of pathogenic bacteria *K. pneumoniae* and the others were belonged to other bacteria: 36 (32.14%) *Pseudomonas* spp., 20 (17.86%) *E. coli*, 10(8.93%) *S.aureus* and 4 (3.57 %) *Proteus* spp., while mixed growth isolates frequency as the following: *K. pneumoniae* and *Pseudomonas* spp. 64 (65.31%), *Pseudomonas* spp. and *E. coli* 18 (18.37%), *K. pneumoniae* and *E. coli* 7(7.14%), *Pseudomonas* spp. and *Proteus* spp. 4 (4.08 %), *K. pneumoniae* and *S.aureus* 3 (3.06 %) and *Proteus* spp. and *E. coli* 2 (2.04 %).

In a local study done by Mohammed(2007), who isolated *K. pneumoniae* from burn wound infection (36.7%) 20[21]; while Assal, (2010) isolated *K. pneumoniae* from wound (31.25%). These results were agreement with this study. Kehinedet.al(2004) also found that *Klebsiella* spp. (34.4%) was the most common isolate from infected burn

wounds [22]. *K. pneumoniae* associated with hospital-acquired infection accounting for 34–36% of cases of *K. pneumoniae* bacteremia [23].

#### Antibiotic Susceptibility Testing

Antimicrobial resistance to the carbapenems (e.g. imipenem and meropenem) mediated by metallo-β-lactamase (MBL) enzymes has remarkable clinical implications since the carbapenems are usually the last options of treatment for bacterial infections caused by multidrug resistant organisms (e.g. producers of extended spectrum B-lactamases) [24]. Eight antibiotic disks were used in this study included two types of Carbapenems antibiotics; Imipenem (IPM), Meropenem (MEM) and two types of third generation Cephalosporins included; Cefotaxime (CAZ), Cefotaxime (CTX). Table(1) summarizes the results of antibiotic susceptibility test and reflects forty-two isolates were resistance to the following antibiotics; Imipenem (21.42%), Meropenem (19.04%), Cefotaxime (69.04%), Cefotaxime (85.71%), Pipracillin (85.71%), gentamicin (26.19%), Amikacin (19.04%) and Ciprofloxacin (59.52).

Furthermore, some isolates exhibited intermediate susceptibility to Imipenem (9.52%), Meropenem (4.76%), Cefotaxime (11.90%), Pipracillin (4.76%), Amikacin (4.76%) and Ciprofloxacin (2.38%). While some isolates showed susceptibility to the antibiotics as the following: Gentamycin and Amikacin (78.57%), Meropenem (76.19%), Imipenem (69.04%), Ciprofloxacin (38.09%), Cefotaxime (19.04%) and both Cefotaxime, Pipracillin (9.52%).

A high degree of resistance to the tested antibiotics was noted among the bacteria isolates especially to the third-generation cephalosporins; Cefotaxime(85.71%), Ceftazidime (69.04%), this results of the study agreement with Ejikeugwu et al., 24[25] who reported that *K. pneumoniae*

show a resistance rates for CTX were (61.5 %), CAZ(38.5 %) and Fluoroquinolones (Ciprofloxacin; CIP show a resistance rate(53.8 %). While the carbapenems used, IPM and MEM, the resistance rates of the *K. pneumoniae* was (12.8 %),(7.7 %) respectively.

**Table 3:** Antimicrobial susceptibility pattern of the bacterial isolates

Antibiotic	Susceptible	Intermediate	Resistant
Imipenem (IPM)	(69.04%)	(9.52%)	(21.42%)
Meropenem (MEM)	(76.19%)	(4.76%)	(19.04%)
Ceftazidime (CAZ)	(19.04 %)	(11.90%)	(69.04%)
Cefotaxime (CTX)	(9.52%)	-	(85.71%)
Piperacillin (Pip)	(9.52%)	(4.76%)	(85.71%)
Gentamicin(GM)	(78.57%)	-	(26.19%)
Amikacin(AK)	(78.57%)	(4.76%)	(19.04 %)
Ciprofloxacin(CIP)	(38.09%)	(2.38%)	(59.52%)

Also studies conducted in Iraq reported that the susceptibility of *K. pneumoniae* isolates collected from clinical and environmental samples to imipenem was (100%) (Al-Asady, 2009; Al-Hilli, 2010). These results relatively in agreement to the present study. Reasons of resistance may be due to inappropriate duration of antibiotic therapy and sub-therapeutic concentrations of the drug [26] or due to other resistance mechanisms including conformational changes in PBPs, permeability changes in the outer membrane and active efflux of the antibiotic [27].

In local studies; at Baghdad city, Rhumaid and Al-Mathkhury [28] referred that the isolates were resistance to antibiotics; Imipenem (5.6%), Meropenem (9.4%), Ceftazidime (58.5%), and Cefotaxime (43.3%). While Al-Qafaji [29] referred that (100%) and (94.5%) of *K. pneumoniae* isolates were resistance to Cefotaxime and Ceftazidime respectively. The present study exhibited sensitivity to Amikacin and Gentamicin (78.57%), Meropenem (76.19%), Imipenem (69.04%) and Ciprofloxacin(38.09%). The results of this study belong to Cefotaxime and Imipenem in compared to local study [30]


was not agree. Results from table (1) revealed that higher resistant rate was found for Piperacillin (85.71%); this result in agreement with a previous studies; Al-Asady (2009) and Al-Hilli (2010) who found that *Enterobacteriaceae* isolates were resistant to piperacillin (100%) and (81%) respectively. High resistance to this class of antibiotics may be due to widespread use of antibiotics in hospitals [31,32].

#### Screening for metallo $\beta$ -lactamases (MBL)

Detection of metallo  $\beta$ -lactamases (MBL) were performed by Meropenem-EDTA double disks method and modified Hodge test. Some carbapenem resistance *K. pneumoniae* isolates were MBL producers. 20 from 30 of isolates(66.6%) showed overnight growth an increase of  $\geq 17$  mm in zone diameter in the presence of 1900  $\mu$ g of EDTA compared to Meropenem disk alone (Figure-1). Also all these isolates showed the presence of a clover leaf-like shaped zone of inhibition around each tested strain, which was interpreted as a phenotypic evidence of MBL production (Figure-2).



**Figure 1:** Meropenem-EDTA double disks method.




**Figure 2:** Modified Hodge test (MHT)


#### Genotypic detection of *bla*NDM-1,2 genes:

PCR was carried out on the DNA of 20 carbapenem resistance *K. pneumoniae* isolates for *bla*NDM-1,2, using specific primer for *bla*NDM-1,2 forward and *bla*NDM-1,2 reverse (Table-2). Amplification was performed in a 25 $\mu$ l volume as recommended by Promega


Master mix instruction. DNA molecular size marker (500-bp ladder for *NDM-1* gene and 1000-bp for *NDM-2* gene). PCR revealed Lanes (K1 to 20) of *K. pneumoniae* isolates showed positive results with *bla*NDM-1 gene (100 %) (table 5) (Fig.3a,b). Lanes (K 2, 10,16,17,18, and 20) show negative results with *bla*NDM-2 genes 6 (30 %). (Fig.4a,b).




**Figure 3a.:** Agarose gel electrophoresis in 1% for *bla* NDM-1 gene product show positive results(1-10).Ethidium bromide stain (0.5%), Amplicon size (500bp), DNA Ladder (100bp), the electric current at 100 volt for 1hr.



**Figure 3 b.:** Agarose gel electrophoresis in 1% for *blaNDM-1* gene product show positive results(11-20). Ethidium bromide stain (0.5%), Amplicon size (500bp), DNA Ladder (100bp), the electric current at 100 volt for 1hr.



**Figure 4 a.:** Agarose gel electrophoresis in 1% for *blaNDM-2* gene product show negative results(2,10). Ethidium bromide stain (0.5%), Amplicon size(1000bp), DNA Ladder (100bp) ,the electric current at 100 volt for 1hr.



**Figure 4 b.:** Agarose gel electrophoresis in 1% for *blaNDM-2* gene product show negative results(16,17,18,20). Ethidium bromide stain (0.5%), Amplicon size (1000bp), DNA Ladder (100bp), the electric current at 100 volt for 1hr.

**Table 5 :** Occurrence of *bla*NDM-1 and 2 genes between *K. pneumoniae* isolates

Frequency	isolates No.	NDM-1 gene	NDM-2 gene
1	1	+	+
2	2	+	-
3	3	+	+
4	4	+	+
5	5	+	+
6	7	+	+
7	8	+	+
8	9	+	+
9	11	+	+
10	12	+	-
11	13	+	+
12	14	+	+
13	15	+	+
14	16	+	+
15	17	+	+
16	21	+	-
17	31	+	-
18	35	+	-
19	39	+	+
20	40	+	-

This is the first report of *bla*NDM-1 and *bla*NDM-2 genes in Baghdad hospitals among *K. pneumoniae* isolates. There were many types of *bla*NDM gene which was located mostly onto conjugative plasmids belonging to several incompatibility groups [32]. So an important consideration should be taken when designing genetic tools to the target carbapenem resistance genes. The occurrence of isolates contain *bla*NDM in Baghdad hospitals may be resulted from transfer of plasmid among resistant isolates from medical care purpose which may helped in acquiring NDM gene when many Iraqi patients were travelled to India and to other countries for medical care purpose. Comparing our results that showed high prevalence of NDM-1 and 2 genes, with a study was carried out in the period between April 2009 and February 2011 in Mubarak Al Kabeer Hospital in Kuwait agreed with our results; three isolates were NDM-1 positive in *K. pneumoniae* [33]. Multiple reports showed infected cases with NDM-1 positive organisms; 44 isolates with NDM-1 were identified in south India (Chennai), 26 in north India (Haryana), 37 in the UK, and 73 in other sites in India and Pakistan

[34]. While Molecular investigations revealed the first identification of the NDM-1 gene in Australia [35] from a man who had been previously hospitalized in Bangladesh and then transferred to Australia.

In local study which was carried out in Hillah hospital by AL-Harmoosh and Jarallah [36] revealed the first identification of the NDM-1,2 genes in Iraq harbored *Acinetobacter baumannii* isolates among patients with different infections.

### **Conclusion**

The study had shown the spreading of *bla*NDM *K. pneumoniae* isolates among patients with burn infections. The rapid spread of *bla*NDM genes of *K. pneumoniae* isolates among patients with burn infections in this study poses an increased threat to hospitalized patients in Iraq and more importantly, avoiding misuse, overuse of antibiotics may converse the undesired effects of multidrug resistant and NDM producing bacteria. Furthermore we would expect more NDM variants to be discovered in the next years in Iraq.



## References

- Appelgren, P.V.; Bjornhagen, K.; Bragderyd, C.; E Jonsson and Ransjo, U.A prospective study of infections in burn patients, *Burns*, 2002; 28:39–46.
- Alves, M. S.; Dias, R. C.; de Castro, A. C.; Riley, L. W. and Moreira, B. M. (2006). Identification of clinical isolates of indole-positive and indole-negative *Klebsiella* spp. *J.Clin. Microbiol.* 44: 3640-3646.
- Ko, W.C., Paterson, D.L., Sagnimeni, A.J., Hansen, D.S., Von Gottberg, A., Mohapatra, S.; Casellas, J.M.;Goossens, H.; Mulazimoglu, L; Trenholme, G.;Klugman,K.P.;McCormack, J.G., Yu, V.L. (2002). Community-acquired *Klebsiella pneumoniae* bacteremia: global differences in clinical patterns.
- Hegggers, J.P.; Hawkins, H.;P. Edgar,; Villarreal, C., Herndon, D. N. 2002. Treatment of infections in burns, In D. N. Herndon (ed.), *Total burn care*. Saunders, London, England, pp. 120–169.
- Nordmann, P.; Naas, T. and Poirel, L. 2011. Global spread of carbapenemaseproducing enterobacteriaceae. *Emerg Infect Dis* 17: 1791 – 1798.
- Al-Charrakh AH, Al-Awadi SJ, Mohammed AS.Detection of Metallo-β-lactamase Producing *Pseudomonas aeruginosa* Isolatedfrom Public and Private Hospitals in Baghdad, Iraq. *Acta Med Iran*, 2016; 54(2):107-113.
- Al-Charrakh AH, Yousif SY, Al-JanabiHS.Occurrence and detection of extended-spectrum β-lactamases in *Klebsiella* isolates in Hilla, Iraq. *Afr J Biotechnol*2011; 10(4): 657-665.
- Giske, CG.; Sundsfjord, AS.; Kahlmeter, G. (2009). Redefining extended-spectrum beta-lactamases: balancing science and clinical need. *J Antimicrob Chemother*; 63: 1-4.
- Yong, D.;Toleman, M.A.; Giske, C.G.; Cho, H.S.; Sundman, K.; Lee, K. and Walsh, T.R. (2009). Characterization of a new metallo-beta-lactamase gene, *bla*NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob. Agents Chemother.* 53(12):5046–5054.
- Fallah, F.; Taherpour, A.; Vola, M.H. and Hashemi, A. (2011). Global spread of New Delhi metallo-beta-lactamase-1(NDM-1). *Iran. J. Clin. Infect. Dis.*6(4):171-176.
- Maya, J.J.; Ruiz, S.J.; Blanco, V.M.; Gotuzzo, E.; Guzman-Blanco, M.; Labarca, J.; Salles, M.; Quinn, J.P. and Villegas, M.V.(2013). Current status of carbapenemases in Latin America. *Expert Rev. Anti. Infect. Ther.*2013, 11, 657–667.
- Bonomo, R.A. (2011). New Delhi-metallo-β-lactamase and multidrug resistanc: a global SOS?.*Clin.Infect.Dis.*52(4) : 485-448.
- Lai CC.; Wu UI.; Wang JT. and Chang SC.(2013). Prevalence of carbapenemase-producing *Enterobacteriaceae*and its impact onclinical outcomes at a teaching hospital in Taiwan. *J FormosMed Assoc*;112:492–496.
- MacFaddin, J.F. *Biochemical tests for identification of medical bacteria*. 3rd ed. Lippincott Williams and Wilkins, USA;2000.
- Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 22nd informational supplement. CLSI document M100-S22. CLSI, Wayne, PA.
- Shahcheraghi F.; Nikbin VS. and Feizabadi M. 2010. Identification and genetic characterization of metallo-beta-lactamase producing strains of *Pseudomonas aeruginosa* in Tehran, Iran. *New Microbiologica*; 33: 243-248.
- Lee, K., Lim, Y.S., Yong, D., Yum, J. H. and Chong, Y. (2003). Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J. Clin. Microbiol.*, 41(10): 4623-4629.
- Lee, K., Chong, Y., Shin, H. B., kim, Y.A., Yong, D. and Yum, J. H. 2001. Modified Hodge and EDTA-disc synergy tests to screen metallo-β-lactamase-producing strains of *Pseudomonas* and *Acinetobacter* species. *Clin. Microbiol.Infect.*,7: 88-91.
- Queenan, A. M. and Bush, K. (2007). Carbapenemases: the versatile beta-lactamases. *Clin. Microbiol. Rev.*, 20(3):440-458.
- Magdeldin, S. (2012). Gel electrophoresis–Principle and basics. InTech. Rijeka, Croatia.
- Mohammed, W. Sinai(2007).Isolation and Identification of Aerobic Pathogenic Bacteria

- From Burn Wound Infections. J Al-Nahrain Univ Sci 2007; 10(2): 94-97.
22. Kehinde, A.O. ; Ademla, S.A.; Okesola, A.O. ; Oluwatosin, O.M. and Bakare, R.A. (2004). Pattern of bacterial pathogens in burn wound infections in Ibadan, Nigeria, Annals of burns and fire disasters, vol. XVII, No. 1, pp.1-5.
  23. Tsai, S.S., Huang, J.C., Chen, S.T., Sun, T.H., Wang, C.C., Lin, S.F., N Hsu, B.R.S., Lin, J.D., Huang, S.U. and Huang, Y.Y. 2010. Characteristics of *Klebsiella pneumoniae* Bacteremia in Community-acquired and Nosocomial Infections in Diabetic Patients. Chang Gung Med J. 33(5), pp: 532-539.
  24. K. Dzierzanowska-Fangrat; K. Semczuk; U. Ęopaciuk; J. Kurlenda; E. Matafie; E. Puacz; E. Stalmaska- Dworak and D. Dzierzanowska (2005). Antimicrobial susceptibility of aerobic microorganisms isolated from intra-abdominal infections in pediatric patients in Poland. Med Sci Monit, 11(5): 241-245.
  25. Ejikegwu Chika; Ugwu Chigozie; Duru Carissa; kegbunam Moses; Irohafeanyichukwu and Esimone Charles (2013). Phenotypic Detection of Metallo-B-lactamase Enzyme in Enugu, Southeast Nigeria. African J. Basic & Appl. Sci., 5 (5): 214-219.
  26. Philippe, E.; Weiss, M.; Shultz, JM.; Yeomans, F. and Ehrenkranz, NJ. (1999). Emergence of highly antibiotic-resistant *Pseudomonas aeruginosa* in relation to duration of empirical antipseudomonal antibiotic treatment. Clin. Perform. Qual. Health Care. 7: 83-87.
  27. Amyes S.G. (2003). Resistance to beta-lactams-the permutations. J. Chemother. 15 (6): 525-535.
  28. Rhumaid, A.K. and Al-Mathkhury H.J.F., (2015). Detection of *bla*KPC Gene in Some Clinical *Klebsiella pneumoniae* Isolates in Baghdad. Iraqi Journal of Science, Vol 56, No. 4A, pp: 2853-2861.
  29. Al-Qafaji, M.H.M. 2008. Biofilm Formation by The External Fixators Contaminating *Klebsiella pneumoniae* and Its Antibiotic Resistance. M.Sc. thesis. College of Science, University of Baghdad, Baghdad Iraq.
  30. Al-Asady, F.M.H. (2009). Bacteriological study on extended-spectrum beta-lactamases produced by Enterobacteriaceae isolated from children with bacteremia in Hilla city. M.Sc. Thesis. College of Medicine, Babylon University.
  31. Al- Hilli, Z. B. (2010). Dissemination of  $\beta$ -lactamases in *Escherichia coli* and *Klebsiella* spp. isolated from Merjan teaching hospital in Hilla city. M.Sc Thesis, College of Sciences, Kufa University.
  32. Dortet L., Poirel L., Nordmann P. (2014). Worldwide dissemination of the NDM-type carbapenemases in Gram-negative bacteria. Biomed Res. Int. 2014;249856. 10.1155/2014/249856
  33. Jamal W. Y.; Rotimi V. O.; Albert M. J.; Khodakhost F.; Nordmann P. and Poirel L. (2013). High prevalence of VIM-4 and NDM-1 metallo- $\beta$ -lactamase among carbapenem-resistant Enterobacteriaceae. J Med Microbiol. jmm.0.059915-0
  34. Kumarasamy K.; Toleman MA. and Walsh, TR (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 10(9):597-602.
  35. Poirel L. B.; Lagrutta E.; Taylor P.; Pham J. and Nordmann P. (2010). Emergence of metallo  $\beta$ -lactamase NDM-1 producing multidrug resistant *Escherichia coli* in Australia. Antimicrob. Agents Chemother. 54:4914-4916.
  36. AL-Harmoosh, R. A. And Eman M. Jarallah (2015). First detection of the *bla*NDM-1 and *bla*NDM-2 genes in clinical isolates of *Acinetobacter baumannii* in Hillah hospitals-IRAQ. International Journal of Advanced Research, 3(10):1407 – 1416.